Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
COSCIENS Biopharma Inc. (T.CSC) had Return on Tangible Equity of -116.32% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
-20.98M |
|
-- |
|
-- |
|
-- |
|
-19.22M |
|
-- |
|
-20.87M |
|
-15.03M |
|
-20.98M |
|
-20.98M |
|
-20.98M |
|
-15.18M |
|
-19.22M |
|
-18.19M |
|
2.58M |
|
2.58M |
|
-8.13 |
|
-8.13 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
48.07M |
|
-- |
|
-- |
|
-- |
|
30.03M |
|
18.04M |
|
18.04M |
|
18.04M |
|
3.14M |
|
| Cash Flow Statement Financials | |
-19.97M |
|
34.38M |
|
-0.81M |
|
9.15M |
|
22.47M |
|
13.32M |
|
0.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.32 |
|
-- |
|
-- |
|
0.13 |
|
0.18 |
|
49.33% |
|
-146.27% |
|
-146.27% |
|
-138.44% |
|
-158.81% |
|
-159.69% |
|
-21.56M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
1.81 |
|
3.88 |
|
94.08 |
|
-116.32% |
|
|
Return on Tangible Equity |
-116.32% |
-43.65% |
|
-100.72% |
|
5.74 |
|
-8.35 |
|
-7.74 |
|